Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials

Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials

Source: 
Pharmaceutical Business Review
snippet: 

Novartis said that its human anti-CD20 monoclonal antibody ofatumumab (OMB157) showed superiority over Aubagio (teriflunomide) in two phase 3 trials in patients with relapsing forms of multiple sclerosis (RMS).